Mechanism
Leuprolide is a synthetic nonapeptide analog of native GnRH (gonadotropin-releasing hormone), with two modifications: D-leucine substituted at position 6 (extending half-life) and the C-terminal glycine replaced with N-ethyl amide (further stabilization).
Native GnRH is released in pulses from the hypothalamus and stimulates LH/FSH secretion from the anterior pituitary. The pulsatile pattern is critical — continuous high-amplitude GnRH receptor stimulation downregulates the receptor and suppresses LH/FSH secretion after an initial 1–2 week surge.
Leuprolide exploits this paradox. Continuous administration (depot or daily injection) saturates the receptor, drives downregulation, and within 2–4 weeks reduces serum testosterone in men to castrate levels (<50 ng/dL) and estradiol in women to postmenopausal levels.
The “flare phenomenon” — initial testosterone/estrogen surge in the first 1–2 weeks — is clinically significant in prostate cancer, where it can theoretically worsen bone metastases or spinal cord compression. Standard prostate cancer protocols co-administer an antiandrogen (bicalutamide) for the first 2–4 weeks to block the flare effect.
Available formulations: daily subcutaneous injection (rare now), monthly depot (3.75 mg, 7.5 mg), 3-monthly depot (11.25 mg, 22.5 mg), 4-monthly depot (30 mg), and 6-monthly depot (45 mg). A new ready-to-use 3-month leuprolide mesylate formulation (Camcevi) was FDA-approved August 29, 2025 for advanced prostate cancer, achieving testosterone suppression in 97.9% of patients by day 28 and maintaining levels through day 168 — adding to the 6-month leuprolide mesylate Camcevi formulation approved in May 2021.
What the evidence shows
Advanced prostate cancer: Leuprolide has been the backbone of androgen deprivation therapy (ADT) for ~40 years. Multiple large trials established it as equivalent to surgical orchiectomy for testosterone suppression. It remains standard-of-care for metastatic and locally advanced disease, often combined with newer agents (abiraterone, enzalutamide, apalutamide, darolutamide).
Endometriosis: Multiple RCTs show leuprolide reduces pelvic pain and lesion size versus placebo and active comparators. Typically used in 6-month courses with hormonal “add-back” therapy to limit bone density loss.
Central precocious puberty: Leuprolide depot is the standard treatment for children with central precocious puberty (CPP), suppressing premature pubertal development. Long safety record in this population since the 1990s.
Uterine fibroids: Pre-surgical use to reduce fibroid size and uterine bleeding before myomectomy or hysterectomy.
Gender-affirming care: Increasingly used as a “puberty blocker” in transgender adolescents, an indication with growing but politically contested clinical evidence base. Outside the scope of this monograph beyond noting the use exists.
Dosing literature
Approved dosing varies by indication and formulation:
- Prostate cancer (Lupron Depot): 7.5 mg monthly, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months — equivalent castration profiles
- Endometriosis: 3.75 mg monthly or 11.25 mg every 3 months for 6 months (with hormonal add-back)
- Central precocious puberty: 7.5–15 mg monthly depot, dose by weight; or 11.25–30 mg every 3 months
The 6-monthly formulation (Eligard 45 mg) is increasingly preferred for prostate cancer maintenance — patient burden is dramatically lower.
Risks and adverse events
Hypogonadism-related (expected, dose-dependent):
- Hot flashes (very common, often severe)
- Loss of libido, erectile dysfunction in men
- Vaginal dryness, mood changes in women
- Bone density loss with long-term use — clinically significant after 1+ year
- Loss of muscle mass, weight gain, fatigue
Other:
- Injection site reactions (depot formulations can cause sterile abscess or granuloma)
- Hyperglycemia, increased cardiovascular event rate (in prostate cancer ADT context — partly hypogonadism-mediated)
- Initial flare effect in first 2 weeks (manage with antiandrogen co-administration)
- Mood/depression — well-documented but variable
Long-term concerns:
- Bone density loss requires monitoring (DEXA scans) and often bisphosphonate or denosumab co-treatment
- Increased risk of cardiovascular events in long-term ADT patients — recognized in oncology guidelines
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Approved (Lupron, Eligard, multiple generics) | |
| European Union | Approved | |
| United Kingdom | Approved | NHS standard for prostate cancer ADT. |
| Most major markets | Approved |
Generic leuprolide depot is available in most markets; brand-name competition includes Eligard (depot polymer, slightly different release profile), Trelstar (triptorelin, related drug), and Zoladex (goserelin, related drug).
Where to get it
Through a clinician (oncology for prostate cancer, gynecology for endometriosis/fibroids, endocrinology for CPP) and a specialty or hospital pharmacy. Not a self-administered drug.
We have no fulfillment partner for leuprolide. (See How we make money.)
References (selected)
- Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. *N Engl J Me
Quick Facts
| Also Known As | Leuprorelin, Leuprolide acetate, TAP-144, Lupron, Eligard, Viadur |
|---|---|
| Sequence | pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt |
| Molecular Formula | C59H84N16O12 |
| Molecular Weight | 1209.4 Da |
| PubChem CID | 657181 |
Research Parameters
| Half-Life | ~3 hours (following subcutaneous injection of non-depot formulation). Depot formulations have prolonged release over weeks to months. |
|---|---|
| Stability | Lyophilized powder is stable at recommended storage conditions for extended periods. After reconstitution with provided diluent, immediate use is recommended. Specific stability data for research-grade lyophilized powder varies by manufacturer; typical guidance is 28 days at 2-8°C after reconstitution in bacteriostatic water, though many protocols recommend use within 24 hours. |
| Solubility | Bacteriostatic Water for Injection (0.9% benzyl alcohol), Sterile Water for Injection. The commercial depot microsphere formulations use specialized diluents. |
| Vial Size | 5 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture. For long-term storage, -80°C is recommended. |
| Storage (Reconstituted) | 2-8°C (refrigerated) for short-term storage if necessary, but immediate use is strongly advised. Do not freeze reconstituted solution. |
| Typical Research Dose | 1000-2000 mcg/day (1-2 mg/day) for non-depot research protocols. Depot formulations are dosed in mg ranges (e.g., 3750 mcg/3.75 mg per month). |
| Cycle Parameters | Research protocols vary widely. For continuous hormonal suppression, daily subcutaneous injection or administration of a long-acting depot formulation (e.g., every 28 days, 84 days, or 168 days) for the duration of the study, which can be several weeks to multiple years in chronic models. |
| Amino Acid Count | 11 |
Mechanism of Action
Leuprolide acts as a potent agonist at the gonadotropin-releasing hormone receptor (GnRHR) in the anterior pituitary. Its mechanism is characterized by an initial stimulatory phase followed by profound and sustained suppression.
Initial Agonist Phase: Upon first administration, Leuprolide binds to and activates the GnRHR on pituitary gonadotrophs. This triggers the phospholipase C/IP3 pathway, leading to calcium mobilization and the release of stored luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This causes a transient surge in serum sex steroid levels (testosterone or estrogen).
Receptor Downregulation and Desensitization: With continuous, non-pulsatile stimulation by the long-acting agonist, the GnRHR undergoes internalization and is not efficiently recycled to the cell membrane. Concurrently, post-receptor signaling pathways become desensitized. This disrupts the normal pulsatile signaling required for physiological gonadotropin synthesis and release.
Pituitary-Gonadal Axis Suppression: The downregulated and desensitized state leads to a dramatic decrease in the secretion of LH and FSH. This results in severely reduced stimulation of the gonads (testes or ovaries), plunging circulating levels of testosterone and estrogen to castrate or post-menopausal ranges. This state of medical castration is maintained for the duration of continuous agonist exposure.
Research Applications
Oncology Research: Leuprolide is extensively used in preclinical and clinical cancer research, particularly for hormone-sensitive malignancies. In prostate cancer models, it is employed to induce androgen deprivation, studying tumor regression, mechanisms of castration resistance, and combination therapies. In breast cancer and endometriosis research, it is used to create hypoestrogenic states to evaluate tumor growth dynamics and the effects of estrogen deprivation.
Endocrinology and Reproductive Biology: Research utilizes Leuprolide to create controlled models of hypogonadism to study the systemic effects of sex hormone ablation. This includes investigations into bone mineral density loss, metabolic changes, body composition shifts, and cardiovascular parameters. It is also a key tool in studying the central control of puberty and in protocols for controlled ovarian stimulation in assisted reproduction.
Preclinical Model Development: The peptide is instrumental in establishing animal models of hormone-dependent conditions. By providing reliable and reversible chemical castration, it allows researchers to isolate the effects of sex steroids in studies on behavior, metabolism, inflammation, and tissue-specific physiology without the confounding variables of surgical castration.
Safety & Side Effects
From clinical and animal studies, side effects are primarily a consequence of its intended mechanism of action (hypogonadism). Common effects include hot flashes, sweating, loss of libido, erectile dysfunction, gynecomastia, and injection site reactions. Longer-term concerns include significant loss of bone mineral density (osteoporosis risk), potential negative impacts on lipid profiles, and metabolic changes. The initial testosterone or estrogen 'flare' in the first 1-2 weeks can temporarily worsen symptoms in conditions like prostate cancer (bone pain, urinary obstruction) or endometriosis (pain), which is often managed with concurrent anti-androgen or other therapy. Anecdotal reports from clinical use sometimes include mood swings, fatigue, and muscle mass loss. Theoretical concerns exist regarding cardiovascular risk with long-term use, though evidence is mixed.
Dosage Information
This information is derived from published research and clinical protocols for context. All use in humans is strictly prescription-based.
In clinical practice and related research, dosing is highly formulation-dependent. For daily subcutaneous injection in research settings, doses range from 1 mg/day. Depot formulations (e.g., 1-month, 3-month, 6-month) deliver doses such as 3.75 mg, 7.5 mg, 11.25 mg, 15 mg, or 22.5 mg via intramuscular or subcutaneous injection at intervals corresponding to the depot duration. The frequency is a single injection per depot period (e.g., every 28 days for a 1-month formulation). Duration of administration in research protocols varies from several weeks to years, depending on the experimental model, such as the length of a tumor study or the duration of hormonal suppression required.
References
Schally, A.V., Kastin, A.J., Arimura, A. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971; 173:1036-1038.
Periti, P., Mazzei, T., Mini, E. Clinical pharmacokinetics of depot leuprorelin. Clinical Pharmacokinetics 2002; 41(7):485-504.
Sharifi, R., Bruskewitz, R.C., Gittleman, M.C., et al. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clinical Therapeutics 1996; 18(4):647-657.
Conn, P.M., Crowley, W.F. Gonadotropin-releasing hormone and its analogs. Annual Review of Medicine 1994; 45:391-405.
Broggini, M., Buraggi, G.L., Recchia, M., et al. Pharmacokinetics and pharmacodynamics of the luteinizing hormone-releasing hormone (LHRH) analogue leuprorelin in prostate cancer patients. British Journal of Clinical Pharmacology 1991; 31(3):311-317.
Matsuo, H., Baba, Y., Nair, R.M., Arimura, A., Schally, A.V. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochemical and Biophysical Research Communications 1971; 43(6):1334-1339.